nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

29.09.2016 | Review – Cancer Research

Metastasis: an early event in cancer progression

verfasst von: Yijun Hu, Xiya Yu, Guixia Xu, Shanrong Liu

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Metastasis is the leading cause of death for a majority of cancer patients, and thus the need to understand the biology of metastasis becomes increasingly acute. When metastasis is initiated in tumor progression remains obscure. Better understanding of mechanisms regulating acquisition of metastatic ability in tumor cells will provide novel therapeutic targets and prevention of metastasis in clinics accompanied with the treatment of the primary tumor might be helpful in reducing metastasis-related mortality.

Methods

A literature search was performed in multiple electronic databases. Research papers from clinical reports to experimental studies on metastasis were analyzed.

Results

The article discusses tumor heterogeneity and genomic instability in the context of metastasis and tumor cell dissemination. And then we review biological mechanism of metastasis at an early stage in both intracellular (CSCs and CTCs) and extracellular (microenvironment) context. Finally, current development of anti-metastatic therapies is summarized.

Conclusions

Metastasis could be initiated at an early point of tumor progression. Therefore, early intervention on metastasis should be applied among cancer patients in clinical settings.

Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L (2001) Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 12(4):863–879PubMedPubMedCentralCrossRef

Al-Assar O, Demiciorglu F, Lunardi S, Gaspar-Carvalho MM, McKenna WG, Muschel RM et al (2014) Contextual regulation of pancreatic cancer stem cell phenotype and radioresistance by pancreatic stellate cells. Radiother Oncol 111(2):243–251PubMedCrossRef

Alderton GK (2015) Tumour microenvironment: driving relapse. Nat Rev Cancer 15(4):195PubMedCrossRef

Alix-Panabières C, Pantel K (2014) Challenges in circulating tumour cell research. Nat Rev Cancer 14(9):623–631PubMedCrossRef

Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G et al (2006) Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res Off J Am Assoc Cancer Res 12(19):5615–5621. doi:10.1158/1078-0432.ccr-06-0169 CrossRef

Becker PS (2012) Dependence of acute myeloid leukemia on adhesion within the bone marrow microenvironment. Sci World J 2012:856467. doi:10.1100/2012/856467 CrossRef

Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T et al (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol Off J Am Soc Clin Oncol 25(10):1160–1168. doi:10.1200/jco.2005.04.7118 CrossRef

Beliveau A, Mott JD, Lo A, Chen EI, Koller AA, Yaswen P et al (2010) Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo. Genes Dev 24(24):2800–2811. doi:10.1101/gad.1990410 PubMedPubMedCentralCrossRef

Bernards R, Weinberg RA (2002) Metastasis genes: a progression puzzle. Nature 418(6900):823PubMedCrossRef

Bissell MJ, Kenny PA, Radisky DC (2005) Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol 70:343–356. doi:10.1101/sqb.2005.70.013 PubMedPubMedCentralCrossRef

Bissig H, Richter J, Desper R, Meier V, Schraml P, Schaffer AA et al (1999) Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. Am J Pathol 155(1):267–274. doi:10.1016/s0002-9440(10)65120-6 PubMedPubMedCentralCrossRef

Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467(7315):596–599. doi:10.1038/nature09454 PubMedPubMedCentralCrossRef

Bourzac K (2014) Biology: three known unknowns. Nature 509(7502):S69–S71. doi:10.1038/509S69a PubMedCrossRef

Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion: migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer 5(9):744–749. doi:10.1038/nrc1694 PubMedCrossRef

Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–802. doi:10.1056/NEJMoa050434 PubMedCrossRef

Catena R, Bhattacharya N, El Rayes T, Wang S, Choi H, Gao D et al (2013) Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov 3(5):578–589. doi:10.1158/2159-8290.cd-12-0476 PubMedPubMedCentralCrossRef

Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B et al (2010) Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 16(1):45–55. doi:10.1158/1078-0432.ccr-09-1630 CrossRef

Chen A, Cuevas I, Kenny PA, Miyake H, Mace K, Ghajar C et al (2009) Endothelial cell migration and vascular endothelial growth factor expression are the result of loss of breast tissue polarity. Cancer Res 69(16):6721–6729. doi:10.1158/0008-5472.can-08-4069 PubMedPubMedCentralCrossRef

Cheng L, Bostwick DG, Li G, Wang Q, Hu N, Vortmeyer AO et al (1999) Allelic imbalance in the clonal evolution of prostate carcinoma. Cancer 85(9):2017–2022PubMedCrossRef

Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD et al (2006) CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 66(1):32–48. doi:10.1002/pros.20318 PubMedCrossRef

Clevers H (ed) (2015) Tracking cancer stem cells: the intestine paradigm. 2015 AAAS Annual meeting (12–16 February 2015): aaas

Cohen SJ, Alpaugh RK, Gross S, O’Hara SM, Smirnov DA, Terstappen LW et al (2006) Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 6(2):125–132PubMedCrossRef

Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer—trials and tribulations. Science 295(5564):2387–2392PubMedCrossRef

Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791PubMedCrossRef

Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA et al (2009) High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 13(8b):2236–2252. doi:10.1111/j.1582-4934.2008.00455.x PubMedCrossRef

Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O et al (2011) Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 9(4):357–365. doi:10.1016/j.stem.2011.08.010 PubMedCrossRef

Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17(10):1253–1270. doi:10.1101/gad.1061803 PubMedPubMedCentralCrossRef

Emlet DR, Gupta P, Holgado-Madruga M, Del Vecchio CA, Mitra SS, Han S-Y et al (2014) Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. Cancer Res 74(4):1238–1249PubMedCrossRef

Engel J, Eckel R, Kerr J, Schmidt M, Fürstenberger G, Richter R et al (2003) The process of metastasisation for breast cancer. Eur J Cancer 39(12):1794–1806PubMedCrossRef

Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M et al (2010) Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Investig 120(6):2030–2039. doi:10.1172/jci42002 PubMedPubMedCentralCrossRef

Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C et al (2006) A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107(5):885–892PubMedCrossRef

Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9):809–819. doi:10.1056/NEJMoa1002011 PubMedPubMedCentralCrossRef

Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1(5):621–632PubMedCrossRef

Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A et al (2012) The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 150(4):764–779. doi:10.1016/j.cell.2012.06.035 PubMedPubMedCentralCrossRef

Gao F, Zhao ZL, Zhao WT, Fan QR, Wang SC, Li J et al (2013) miR-9 modulates the expression of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells. Biochem Biophys Res Commun 431(3):610–616. doi:10.1016/j.bbrc.2012.12.097 PubMedCrossRef

Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F et al (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol Off J Am Soc Clin Oncol 27(34):5700–5706. doi:10.1200/jco.2009.23.2025 CrossRef

Govaert KM, Emmink BL, Nijkamp MW, Cheung ZJ, Steller EJ, Fatrai S et al (2014) Hypoxia after liver surgery imposes an aggressive cancer stem cell phenotype on residual tumor cells. Ann Surg 259(4):750–759PubMedCrossRef

Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10(5):593–601. doi:10.1038/ncb1722 PubMedCrossRef

Guo W, Xue J, Shi J, Li N, Shao Y, Yu X et al (2010) Proteomics analysis of distinct portal vein tumor thrombi in hepatocellular carcinoma patients. J Proteome Res 9(8):4170–4175PubMedCrossRef

Gutschner T, Diederichs S (2012) The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 9(6):703–719. doi:10.4161/rna.20481 PubMedPubMedCentralCrossRef

Harmer MH (ed) (1978) TNM classification of malignant tumours. The Union

Hayes DF, Smerage JB (2009) Circulating tumor cells. Progr Mol Biol Transl Sci 95:95–112CrossRef

Hood JL, San RS, Wickline SA (2011) Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res 71(11):3792–3801. doi:10.1158/0008-5472.can-10-4455 PubMedCrossRef

Hu Y, Yu X, Liu S, Liu S (2013) Cancer stem cells: a shifting subpopulation of cells with stemness? Med Hypotheses 80(5):649–655PubMedCrossRef

Huang S, Chen Y, Podsypanina K, Li Y (2008) Comparison of expression profiles of metastatic versus primary mammary tumors in MMTV-Wnt-1 and MMTV-Neu transgenic mice. Neoplasia (New York, NY) 10(2):118–124CrossRef

Humphries B, Yang C (2015) The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget 6(9):6472–6498PubMedPubMedCentralCrossRef

Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E et al (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13(1):58–68. doi:10.1016/j.ccr.2007.12.003 PubMedCrossRef

Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M et al (2007) Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 25(33):5194–5202. doi:10.1200/jco.2007.11.7762 CrossRef

Jackisch C, Scappaticci FA, Heinzmann D, Bisordi F, Schreitmüller T, Gv M et al (2015) Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation. Future Oncol 11(1):61–71PubMedCrossRef

Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM et al (2003) MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22(39):8031–8041. doi:10.1038/sj.onc.1206928 PubMedCrossRef

Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J et al (2012) 1 versus 3 years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307(12):1265–1272. doi:10.1001/jama.2012.347 PubMedCrossRef

Jung EK, Leung E, Barker D (2016) Synthesis and biological activity of pyrrole analogues of combretastatin A-4. Bioorg Med Chem Lett 26(13):3001–3005. doi:10.1016/j.bmcl.2016.05.026 PubMedCrossRef

Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3(6):537–549PubMedCrossRef

Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069):820–827. doi:10.1038/nature04186 PubMedPubMedCentralCrossRef

Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L et al (2009) Tumor self-seeding by circulating cancer cells. Cell 139(7):1315–1326. doi:10.1016/j.cell.2009.11.025 PubMedPubMedCentralCrossRef

Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9(4):302–312. doi:10.1038/nrc2627 PubMedCrossRef

Klein CA, Hölzel D (2006) Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle 5(16):1788–1798PubMedCrossRef

Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH et al (2002) Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet (London, England) 360(9334):683–689. doi:10.1016/s0140-6736(02)09838-0 CrossRef

Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T et al (2011) Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 71(20):6320–6326. doi:10.1158/0008-5472.can-11-1021 PubMedCrossRef

Koppelmans V, de Groot M, de Ruiter MB, Boogerd W, Seynaeve C, Vernooij MW et al (2014) Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy. Hum Brain Mapp 35(3):889–899PubMedCrossRef

Korpal M, Lee ES, Hu G, Kang Y (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283(22):14910–14914. doi:10.1074/jbc.C800074200 PubMedPubMedCentralCrossRef

Koscielny S, Tubiana M, Le MG, Valleron AJ, Mouriesse H, Contesso G et al (1984) Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 49(6):709–715PubMedPubMedCentralCrossRef

Krebs MG, Sloane R, Priest L, Lancashire L, Hou J-M, Greystoke A et al (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29(12):1556–1563PubMedCrossRef

Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A et al (2005) Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23(7):879–894. doi:10.1634/stemcells.2004-0342 PubMedCrossRef

Kuukasjarvi T, Karhu R, Tanner M, Kahkonen M, Schaffer A, Nupponen N et al (1997) Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 57(8):1597–1604PubMed

Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol 15(3):178–196PubMedPubMedCentralCrossRef

Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014:149185PubMedPubMedCentralCrossRef

Li J, Chen L, Zhang X, Zhang Y, Liu H, Sun B et al. (2014) Detection of circulating tumor cells in hepatocellular carcinoma using antibodies against asialoglycoprotein receptor, carbamoyl phosphate synthetase 1 and pan-cytokeratin. PloS One 9(4):e96185. doi:10.1371/journal.pone.0096185 PubMedPubMedCentralCrossRef

Lim E, Metzger-Filho O, Winer EP (2012) The natural history of hormone receptor-positive breast cancer. Oncology 26(688–694):696

Ling H, Vincent K, Pichler M, Fodde R, Berindan-Neagoe I, Slack FJ et al. (2015) Junk DNA and the long non-coding RNA twist in cancer genetics. Oncogene 34(39):5003–5011PubMedPubMedCentralCrossRef

Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H et al (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17(2):211–215. doi:10.1038/nm.2284 PubMedPubMedCentralCrossRef

Liu S, Guo W, Shi J, Li N, Yu X, Xue J et al (2012) MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol 56(2):389–396. doi:10.1016/j.jhep.2011.08.008 PubMedCrossRef

Liu S, Li N, Yu X, Xiao X, Cheng K, Hu J et al (2013) Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. Gastroenterology 144(5):1031–41.e10. doi:10.1053/j.gastro.2013.01.046 PubMedCrossRef

Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ (2007) The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin 57(4):225–241PubMedCrossRef

Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M et al (2011) VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 20(6):701–714. doi:10.1016/j.ccr.2011.11.002 PubMedPubMedCentralCrossRef

Lu H, Clauser KR, Tam WL, Fröse J, Ye X, Eaton EN et al (2014a) A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol 16(11):1105–1117PubMedPubMedCentralCrossRef

Lu H, Yan CH, Bian Y, Chen Z, Van Waes C (2014b) CK2 phosphorylates and inhibits tumor suppressor TAp73 function to promote cancer stem cell gene expression and phenotype in head and neck cancer. Cancer Res 74(19):1925CrossRef

Martin SS, Ridgeway AG, Pinkas J, Lu Y, Reginato MJ, Koh EY et al (2004) A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene 23(26):4641–4645. doi:10.1038/sj.onc.1207595 PubMedCrossRef

Mitelman F, Johansson B, Mertens F (2007) The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 7(4):233–245. doi:10.1038/nrc2091 PubMedCrossRef

Moreira IS, Fernandes PA, Ramos MJ (2007) Vascular endothelial growth factor (VEGF) inhibition—a critical review. Anti Cancer Agents Med Chem 7(2):223–245CrossRef

Mueller MM, Fusenig NE (2004) Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4(11):839–849PubMedCrossRef

Nagle JA, Ma Z, Byrne MA, White MF, Shaw LM (2004) Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol 24(22):9726–9735. doi:10.1128/mcb.24.22.9726-9735.2004 PubMedPubMedCentralCrossRef

Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L et al (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173):1235–1239PubMedPubMedCentralCrossRef

Nasulewicz A, Wietrzyk J, Wolf FI, Dzimira S, Madej J, Maier JA et al (2004) Magnesium deficiency inhibits primary tumor growth but favors metastasis in mice. Biochim Biophys Acta 1739(1):26–32. doi:10.1016/j.bbadis.2004.08.003 PubMedCrossRef

Nishimura E (2014) Melanoma heterogeneity and cancer stem cell. Gan to kagaku ryoho Cancer Chemother 41(4):433–436

Oskarsson T, Batlle E, Massague J (2014) Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 14(3):306–321. doi:10.1016/j.stem.2014.02.002 PubMedPubMedCentralCrossRef

Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 133(3421):571–573CrossRef

Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK et al (2010) A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 6(6):603–615. doi:10.1016/j.stem.2010.04.001 PubMedCrossRef

Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4(6):448–456. doi:10.1038/nrc1370 PubMedCrossRef

Pantel K, Muller V, Auer M, Nusser N, Harbeck N, Braun S (2003) Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 9(17):6326–6334

Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8(5):329–340. doi:10.1038/nrc2375 PubMedCrossRef

Papayannopoulou T (2004) Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. Blood 103(5):1580–1585. doi:10.1182/blood-2003-05-1595 PubMedCrossRef

Pavlidis N, Khaled H, Gaafar R (2015) A mini review on cancer of unknown primary site: a clinical puzzle for the oncologists. J Adv Res 6(3):375–382PubMedCrossRef

Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G et al (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18(6):883–891. doi:10.1038/nm.2753 PubMedPubMedCentralCrossRef

Piergentili R, Carradori S, Gulia C, De Monte C, Cristini C, Grande P et al (2014) Bladder cancer: innovative approaches beyond the diagnosis. Curr Med Chem 21(20):2219–2236PubMedCrossRef

Podsypanina K, Politi K, Beverly LJ, Varmus HE (2008a) Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc Natl Acad Sci USA 105(13):5242–5247. doi:10.1073/pnas.0801197105 PubMedPubMedCentralCrossRef

Podsypanina K, Du Y-CN, Jechlinger M, Beverly LJ, Hambardzumyan S, Varmus H (2008b) Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321(5897):1841–1844PubMedPubMedCentralCrossRef

Popiolek M, Rider JR, Andrén O, Andersson S-O, Holmberg L, Adami H-O et al (2013) Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol 63(3):428–435PubMedCrossRef

Qin T, Yuan Z, Peng R, Bai B, Shi Y, Teng X et al (2013) HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients. Oncol Targets Ther 6:341–347. doi:10.2147/ott.s40851 CrossRef

Rana S, Malinowska K, Zoller M (2013) Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia (New York, NY) 15(3):281–295CrossRef

Resovi A, Pinessi D, Chiorino G, Taraboletti G (2014) Current understanding of the thrombospondin-1 interactome. Matrix Biol J Int Soc Matrix Biol 37:83–91. doi:10.1016/j.matbio.2014.01.012 CrossRef

Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F et al (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148(1–2):349–361. doi:10.1016/j.cell.2011.11.025 PubMedPubMedCentralCrossRef

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246. doi:10.1016/s1470-2045(11)70393-x PubMedCrossRef

Sarvi S, Mackinnon AC, Avlonitis N, Bradley M, Rintoul RC, Rassl DM et al (2014) CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res 74(5):1554–1565PubMedCrossRef

Schardt JA, Meyer M, Hartmann CH, Schubert F, Schmidt-Kittler O, Fuhrmann C et al (2005) Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 8(3):227–239. doi:10.1016/j.ccr.2005.08.003 PubMedCrossRef

Schmidt F, Efferth T (2016) Tumor heterogeneity, single-cell sequencing, and drug resistance. Pharmaceuticals (Basel, Switzerland). doi:10.3390/ph9020033 PubMed

Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ et al (2003) From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100(13):7737–7742. doi:10.1073/pnas.1331931100 PubMedPubMedCentralCrossRef

Seton-Rogers S (2015) Non-coding RNA: stressed to bits. Nat Rev Cancer 15(6):320PubMedCrossRef

Shaked Y, McAllister S, Fainaru O, Almog N (2014) Tumor dormancy and the angiogenic switch: possible implications of bone marrow-derived cells. Curr Pharm Des 20(30):4920–4933PubMedCrossRef

Shannon KE, Keene JL, Settle SL, Duffin TD, Nickols MA, Westlin M et al (2004) Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247. Clin Exp Metastasis 21(2):129–138PubMedCrossRef

Shen CH, Kim SH, Trousil S, Frederick DT, Piris A, Yuan P et al (2016) Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat Med. doi:10.1038/nm.4155

Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V et al (2014) Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506(7488):328–333PubMedPubMedCentralCrossRef

Shuqun C, Mengchao W, Han C, Feng S, Jiahe Y, Guanghui D et al (2007) Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein. Hepatogastroenterology 54(74):499–502PubMed

Sosa MS, Avivar-Valderas A, Bragado P, Wen HC, Aguirre-Ghiso JA (2011) ERK1/2 and p38alpha/beta signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin Cancer Res Off J Am Assoc Cancer Res 17(18):5850–5857. doi:10.1158/1078-0432.ccr-10-2574 CrossRef

Sosa MS, Bragado P, Aguirre-Ghiso JA (2014) Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 14(9):611–622. doi:10.1038/nrc3793 PubMedPubMedCentralCrossRef

Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12(8):895–904. doi:10.1038/nm1469 PubMedCrossRef

Stoecklein NH, Hosch SB, Bezler M, Stern F, Hartmann CH, Vay C et al (2008) Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 13(5):441–453. doi:10.1016/j.ccr.2008.04.005 PubMedCrossRef

Takebe N, Harris PJ, Warren RQ, Ivy SP (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8(2):97–106PubMedCrossRef

Tanase K, Thies ED, Mäder U, Reiners C, Verburg FA (2015) The TNM system (version 7) is the most accurate staging system for the prediction of loss of life expectancy in differentiated thyroid cancer. Clin Endocrinol (Oxf). doi:10.1111/cen.12765

Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M et al (2014) CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14(3):342–356PubMedCrossRef

Van’t Veer LJ, Dai H, Van De Vijver MJ, He YD, Hart AA, Mao M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536CrossRef

Wang X, Adjei AA (2015) Lung cancer and metastasis: new opportunities and challenges. Cancer Metastasis Rev. doi:10.1007/s10555-015-9562-4

Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H et al (2009) Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(10):1549–1556. doi:10.1200/jco.2008.17.0563 CrossRef

Weng D, Penzner JH, Song B, Koido S, Calderwood SK, Gong J (2012) Metastasis is an early event in mouse mammary carcinomas and is associated with cells bearing stem cell markers. Breast Cancer Res BCR 14(1):R18. doi:10.1186/bcr3102 PubMedCrossRef

Wood SL, Pernemalm M, Crosbie PA, Whetton AD (2014) The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev 40(4):558–566PubMedCrossRef

Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJ, Witt H et al (2012) Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482(7386):529–533. doi:10.1038/nature10825 PubMedPubMedCentralCrossRef

Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P et al (2008) Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13(2):153–166. doi:10.1016/j.ccr.2008.01.013 PubMedCrossRef

Zhang X, Liu S, Hu T, Liu S, He Y, Sun S (2009a) Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology (Baltimore, MD) 50(2):490–499. doi:10.1002/hep.23008 CrossRef

Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M et al (2009b) Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16(1):67–78. doi:10.1016/j.ccr.2009.05.017 PubMedPubMedCentralCrossRef

Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y et al (2013) miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol 15(3):284–294. doi:10.1038/ncb2690 PubMedPubMedCentralCrossRef

Zimmer AS, Steeg PS (2015) Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns. J Mol Med 93(1):13–29PubMedCrossRef

Titel: Metastasis: an early event in cancer progression
verfasst von: Yijun Hu
Xiya Yu
Guixia Xu
Shanrong Liu
Publikationsdatum: 29.09.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-016-2279-0

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Metastasis: an early event in cancer progression

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Alpha tocopherol transfer protein (αTTP) is expressed in endometrial carcinoma and is correlated with FIGO stage and 5-year survival

Overexpression of HepaCAM inhibits bladder cancer cell proliferation and viability through the AKT/FoxO pathway

The role of the general practitioner in cancer care: a survey of the patients’ perspective

Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamine

Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone

Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie